Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on challenges in the management of hidradenitis suppurativa (HS), as well as promising therapies in the pipeline that target specific pathways suggested to play a role in the pathogenesis and pathophysiology of the disease.
Hidradenitis suppurativa (HS) is a difficult disease to manage for dermatologists, but advances continue to be made in clinical research regarding comprehension and treatment of the disease, said Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento.
Transcript
Can you speak on recent advances and unmet needs in HS care management?
HS is definitely a difficult condition to manage. When I kind of think about psoriasis being a little more straightforward than eczema, I think of eczema being more straightforward than HS. So, HS really has this heterogeneous presentation. Sometimes it's just in the groin, sometimes it's in the axilla, sometimes it's both. It can be atypical and just be on the buttocks. We see this range of primary skin lesions. So, papules, pustules, some have nodules; we see prominent scarring.
So, this is really a very heterogeneous disease in presentation. And these are what we need to be taking on in the clinic and also in our clinical studies. We're just teasing out the pathogenesis of this condition. We’re starting to learn those patients who just get it in the axilla vs those that have prominent scarring. And we're starting to learn what that pathophysiology looks like.
There's some exciting advances happening in HS. We had big dramatic improvements in management when TNF [tumor necrosis factor] inhibitors were approved for this condition, but now we're starting to see studies that are quite advanced looking at the possible benefit of [interleukin] IL-17 blockade as a treatment strategy for HS.
There's been studies looking at the IL-1 signaling family and its role into HS’ development of disease around the hair follicle or the follicular unit. So, we're starting to tease out some subtleties that are going to open up the door. I think this will be the next big inflammatory condition that we learn to treat in dermatology. And as we do that, we're going to start taking biopsies of patients at different stages so that we can sort of better phenotype these groups early on, to have understanding about what therapies might be more effective in certain stages of disease. So, this is a really important disease that we tackle.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More